GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Small and Large Bowel/The Exclusion Diet Conundrum and IBS
60

The Exclusion Diet Conundrum and IBS

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated November 1, 2025

The exclusion diet conundrum refers to the debate surrounding the effectiveness and validity of using food-specific IgG (FS-IgG) testing to guide dietary eliminations for managing irritable bowel syndrome (IBS). IBS is a chronic gastrointestinal condition characterized by symptoms like abdominal pain, bloating, diarrhea, or constipation. Some studies suggest that removing foods identified by FS-IgG tests might improve symptoms, but this approach is controversial.

One major issue is that FS-IgG likely reflects foods people commonly eat rather than indicating a harmful immune response or intolerance. IgG antibodies are also found in healthy individuals without IBS, so their role in causing symptoms is unclear. Additionally, in some cases, symptom improvement may result from coincidentally eliminating high-FODMAP foods (like wheat, lactose, or soy), which are known to trigger IBS symptoms in many people. This raises doubts about whether FS-IgG testing itself is effective.

The lack of rigorous controls, reliance on self-reported adherence, and absence of clear mechanisms linking IgG to IBS symptoms further complicate the matter. Overusing IgG testing may lead to unnecessary dietary restrictions, anxiety, or even disordered eating. To resolve this conundrum, future research must focus on well-controlled studies to clarify the role of IgG in IBS and ensure safe, evidence-based dietary recommendations.

Related Q&A

61

Severe Diverticulitis Among Younger Americans

The rise in severe diverticulitis among younger Americans is a concerning trend that reflects significant shifts in the disease's epidemiology. Traditionally associated with older adults, diverticulitis is now...

62

Long-Acting GLP-2 Analogue (Glepaglutide) and Short Bowel Syndrome

Glepaglutide is a long-acting GLP-2 (glucagon-like peptide-2) analogue designed to improve intestinal function and absorption in patients with short bowel syndrome (SBS). SBS is a condition characterized by...

63

Ileal Pouch Anal Anastomosis and Pouch Neoplasm

Ileal Pouch-Anal Anastomosis (IPAA): Ileal Pouch-Anal Anastomosis (IPAA) is a surgical procedure typically performed to restore bowel continuity after the removal of the colon and rectum. It is...

64

Ergosterol, visceral hypersensitivity and IBS

Ergosterol: Ergosterol is a naturally occurring sterol compound found in fungi, particularly in fungal cell membranes. Structurally, it is similar to cholesterol, which is found in animal cells....

65

FIREFLI ingestible capsule enable luminance-based diagnosis of acute mesenteric ischemia,

Yes, the FIREFLI ingestible capsule is a groundbreaking device that enables luminance-based diagnosis of acute mesenteric ischemia (AMI). AMI is a severe condition caused by insufficient blood flow...

66

Hyperbaric oxygen therapy for radiation enteritis

Hyperbaric oxygen therapy (HBOT) has emerged as a promising treatment for radiation enteritis (RE), a debilitating complication affecting up to 80% of patients undergoing pelvic radiotherapy, with 5–20%...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer